13.40
price up icon2.37%   0.31
after-market Dopo l'orario di chiusura: 13.43 0.03 +0.22%
loading
Precedente Chiudi:
$13.09
Aprire:
$13.08
Volume 24 ore:
77,294
Relative Volume:
0.63
Capitalizzazione di mercato:
$117.01M
Reddito:
$123.24M
Utile/perdita netta:
$136.00K
Rapporto P/E:
-670.00
EPS:
-0.02
Flusso di cassa netto:
$-148.99M
1 W Prestazione:
-4.83%
1M Prestazione:
+59.14%
6M Prestazione:
-22.28%
1 anno Prestazione:
-48.06%
Intervallo 1D:
Value
$12.69
$13.67
Intervallo di 1 settimana:
Value
$11.15
$14.78
Portata 52W:
Value
$6.53
$29.40

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name
Nome
Seres Therapeutics Inc
Name
Telefono
617 945 9626
Name
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Name
Dipendente
103
Name
Cinguettio
@SeresTX
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
MCRB's Discussions on Twitter

Confronta MCRB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MCRB
Seres Therapeutics Inc
13.40 108.19M 123.24M 136.00K -148.99M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-08 Downgrade Chardan Capital Markets Buy → Neutral
2024-10-24 Downgrade JP Morgan Neutral → Underweight
2023-06-26 Ripresa Oppenheimer Outperform
2023-04-21 Iniziato JP Morgan Neutral
2021-07-23 Downgrade Goldman Neutral → Sell
2021-05-18 Ripresa Goldman Neutral
2021-03-05 Aggiornamento Chardan Capital Markets Neutral → Buy
2020-09-18 Downgrade Chardan Capital Markets Buy → Neutral
2020-08-18 Iniziato Piper Sandler Overweight
2020-08-11 Reiterato H.C. Wainwright Buy
2020-08-11 Aggiornamento Jefferies Hold → Buy
2019-04-30 Iniziato Jefferies Hold
2018-10-22 Iniziato Chardan Capital Markets Buy
2017-10-13 Iniziato Oppenheimer Outperform
2017-08-04 Reiterato H.C. Wainwright Buy
2017-02-01 Reiterato FBR & Co. Outperform
2016-08-12 Reiterato FBR Capital Outperform
2016-08-01 Downgrade BofA/Merrill Buy → Neutral
2016-08-01 Reiterato H.C. Wainwright Buy
2016-07-29 Ripresa H.C. Wainwright Buy
2016-03-30 Iniziato FBR Capital Outperform
2016-03-03 Iniziato Guggenheim Buy
2016-01-25 Iniziato H.C. Wainwright Buy
2015-10-22 Aggiornamento BofA/Merrill Neutral → Buy
2015-07-22 Iniziato Canaccord Genuity Buy
2015-07-21 Iniziato Goldman Neutral
2015-07-21 Iniziato Leerink Partners Outperform
Mostra tutto

Seres Therapeutics Inc Borsa (MCRB) Ultime notizie

pulisher
Jul 24, 2025

What risks could impact Seres Therapeutics Inc. stock performanceExplosive portfolio gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Will Seres Therapeutics Inc. stock benefit from AI tech trendsHigh-yield capital appreciation - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What institutions are buying Seres Therapeutics Inc. stock nowBreakneck growth rates - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Seres Therapeutics Inc. stock priceUnprecedented growth rates - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Is Seres Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Seres Therapeutics Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Seres Therapeutics Inc. stockSuperior capital gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Seres Therapeutics announces leadership transition - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Seres Therapeutics Soars 10.98% on Leadership Transition - AInvest

Jul 23, 2025
pulisher
Jul 22, 2025

Seres Therapeutics stock jumps after naming co-CEOs By Investing.com - Investing.com Canada

Jul 22, 2025
pulisher
Jul 22, 2025

Seres Therapeutics (MCRB) Announces Transition in Executive Lead - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Seres Therapeutics Announces Leadership Transition - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

Seres Therapeutics to Host Conference Call on August 6, 2025, to Discuss Q2 Financial Results and Business Updates - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 21, 2025

Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st

Jul 20, 2025
pulisher
Jul 18, 2025

what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Seres Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Seres Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Seres Therapeutics Soars 21%—What’s Fueling the Biotech Breakout? - AInvest

Jul 14, 2025
pulisher
Jul 01, 2025

5 Best Microbiome Companies (July 2025) - Securities.io

Jul 01, 2025
pulisher
Jun 30, 2025

Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell 3000E Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 25, 2025

Seres Therapeutics May 2025 slides: SER-155 shows 77% infection reduction in transplant patients - Investing.com Nigeria

Jun 25, 2025
pulisher
Jun 12, 2025

FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus

Jun 12, 2025
pulisher
Jun 02, 2025

Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.

Jun 02, 2025
pulisher
May 28, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World

May 28, 2025
pulisher
May 27, 2025

Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics reports promising biomarker data - Investing.com

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times

May 27, 2025

Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):